Stock listing

Annovis Bio, Inc.

Selected listing: 07X · MUN · EUR · DE

Annovis Bio, Inc. (Munich:07X), Health Technology. Latest release Sep 24, 2026: Annovis Bio Announces Partnership with Weave Bio, AI Regulatory Platform…

07X:MUNEURDEUpdated October 2, 2026

Ticker: Munich:07X
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Munich
Currency: EUR

About Annovis Bio, Inc.

The company focuses on developing therapies for neurodegenerative diseases. Annovis Bio aims to address significant unmet medical needs through its innovative research and development efforts.

Latest news from Annovis Bio, Inc.

Annovis Bio Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's disease

September 24, 2026

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease

September 23, 2026

Annovis to Host Corporate Update Webinar on September 2, 2026

August 25, 2026

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

August 14, 2026

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

July 7, 2026

All Annovis Bio, Inc. news →

Research Annovis Bio, Inc.

Annovis Bio, Inc. company profile

View the public company page for Annovis Bio, Inc. on 6ix.

Annovis Bio, Inc. news

Read company news and market updates connected to Annovis Bio, Inc..

Annovis Bio, Inc. investor events

Find investor webinars, events, and replay context for Annovis Bio, Inc..